[go: up one dir, main page]

SG11201704840RA - Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes - Google Patents

Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes

Info

Publication number
SG11201704840RA
SG11201704840RA SG11201704840RA SG11201704840RA SG11201704840RA SG 11201704840R A SG11201704840R A SG 11201704840RA SG 11201704840R A SG11201704840R A SG 11201704840RA SG 11201704840R A SG11201704840R A SG 11201704840RA SG 11201704840R A SG11201704840R A SG 11201704840RA
Authority
SG
Singapore
Prior art keywords
polydiallymine
diabetes
crosslinked
copolymers
treatment
Prior art date
Application number
SG11201704840RA
Inventor
Pradeep K Dhal
Robert J Miller
Steven C Polomoscanik
Philip Just Larsen
Thomas Huebschle
Thorsten Schmidt
Ian Davison
Peter Mcdonnell
Chinyere Agbugba
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11201704840RA publication Critical patent/SG11201704840RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F226/04—Diallylamine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/08—Epoxidation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0025—Crosslinking or vulcanising agents; including accelerators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/15—Heterocyclic compounds having oxygen in the ring
    • C08K5/151—Heterocyclic compounds having oxygen in the ring having one oxygen atom in the ring
    • C08K5/1515—Three-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C08F26/04—Diallylamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Resins (AREA)
SG11201704840RA 2014-12-18 2015-12-16 Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes SG11201704840RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093751P 2014-12-18 2014-12-18
PCT/US2015/066006 WO2016100456A2 (en) 2014-12-18 2015-12-16 Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
SG11201704840RA true SG11201704840RA (en) 2017-07-28

Family

ID=55221501

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704840RA SG11201704840RA (en) 2014-12-18 2015-12-16 Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes

Country Status (27)

Country Link
US (1) US11267924B2 (en)
EP (1) EP3233090A2 (en)
JP (2) JP6866293B2 (en)
KR (1) KR20170096008A (en)
CN (1) CN107250189A (en)
AR (1) AR103175A1 (en)
AU (1) AU2015362590A1 (en)
BR (1) BR112017012794A2 (en)
CA (1) CA2971204A1 (en)
CL (1) CL2017001579A1 (en)
CO (1) CO2017007119A2 (en)
CR (1) CR20170323A (en)
DO (1) DOP2017000140A (en)
EA (1) EA201791380A1 (en)
EC (1) ECSP17045972A (en)
GT (1) GT201700133A (en)
HK (1) HK1251449A1 (en)
IL (1) IL252899A0 (en)
MA (2) MA41202A (en)
MX (1) MX2017007966A (en)
PE (1) PE20171510A1 (en)
PH (1) PH12017501120A1 (en)
SG (1) SG11201704840RA (en)
TN (1) TN2017000253A1 (en)
TW (1) TW201636030A (en)
UY (1) UY36457A (en)
WO (1) WO2016100456A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI784968B (en) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 Amylin analogues
US10479865B2 (en) * 2017-11-01 2019-11-19 Strides Shasun Limited Process for the preparation of sevelamer carbonate
CN114173560B (en) 2019-08-07 2024-07-09 舒万诺知识产权公司 Articles comprising crosslinked guanidine-containing polymers and uses thereof
WO2021055759A1 (en) * 2019-09-20 2021-03-25 Glyscend, Inc. Substituted phenyl boronic acid containing polymers and methods of use
IL305604A (en) * 2021-03-01 2023-11-01 Tricida Inc Pharmaceutical preparations of cross-linked poly(allylamine) polymer

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2456428A (en) 1944-10-11 1948-12-14 Shell Dev Polyallyl amine and related polymeric amines
BE580490A (en) 1958-07-15 1960-01-08 Merck & Co Inc Compositions and methods for lowering the cholesterol content of the blood
US3104205A (en) 1959-12-17 1963-09-17 Warner Lambert Pharmaceutical Deodorant composition comprising the copper complex of the copolymer of allylamine and methacrylic acid
US3308020A (en) 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3332841A (en) 1961-10-04 1967-07-25 Lilly Co Eli Method of treating hyperacidity
BE640616A (en) 1962-12-19
US3293195A (en) 1963-11-29 1966-12-20 Ritter Pfaudler Corp Ion exchange resins prepared from a mixed resin of vinyl pyridine copolymers and epihalohydrins-polyalkylene polyamines and methods of making and using same
US3624209A (en) 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
DE1927336A1 (en) 1968-06-17 1969-12-18 Upjohn Co Oral dosage form for the prevention of hypercholesterolemia
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US3980770A (en) 1971-06-04 1976-09-14 Pharmacia Aktiebolag Polymerization products containing amino groups useful in serum cholesterol level control
CH604722A5 (en) 1973-02-09 1978-09-15 Sandoz Ag
AR206115A1 (en) 1973-06-11 1976-06-30 Merck & Co Inc PROCEDURE TO PREPARE A NON-BRANCHED AND NON-CROSSLINK LINEAR POLYMER
US4205064A (en) 1973-06-11 1980-05-27 Merck & Co., Inc. Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides]
US4016209A (en) 1975-04-23 1977-04-05 Merck & Co., Inc. 3-[N'-(3-Halopropyl)-N-'-methylamino]-N,N,N-trimethyl-1-propanaminium halide and acid addition salts thereof
US4181718A (en) 1975-12-29 1980-01-01 Mason Norbert S Polyanion-stabilized aluminum hydrogels
US4071478A (en) 1976-06-07 1978-01-31 Merck & Co., Inc. Controlled partially cross-linked 3,3-ionenes
US4183918A (en) 1977-03-08 1980-01-15 Exxon Research & Engineering Co. Detoxifying-medicinal emulsions
GB1573487A (en) 1977-05-23 1980-08-28 Bristol Myers Co Bile acid binding composition
US4143130A (en) 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4368725A (en) 1977-11-11 1983-01-18 Mcclintock Michael Solar energy collector
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4247393A (en) 1979-01-11 1981-01-27 Wallace Richard A Hemodialysis assist device
US4439419A (en) 1980-02-20 1984-03-27 The Upjohn Company Method of treating gastric hyperacidity in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance as epichlorhydrin
US4344993A (en) 1980-09-02 1982-08-17 The Dow Chemical Company Perfluorocarbon-polymeric coatings having low critical surface tensions
IE52006B1 (en) 1980-12-12 1987-05-13 Smith & Nephew Ass Polymers of diallyl ammonium monomers pharmaceutical compositions thereof
US4504640A (en) 1982-05-19 1985-03-12 Nitto Boseki Co., Ltd. Process for producing monoallylamine polymer
JPS6090243A (en) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd Method for producing small spherical monoallylamine cross-linked polymer
EP0162388B1 (en) 1984-05-11 1989-09-13 Bristol-Myers Company Novel bile sequestrant resin and uses
US4631305A (en) 1985-03-22 1986-12-23 The Upjohn Company Polymeric material as a disintegrant in a compressed tablet
DE3541511A1 (en) 1985-11-19 1987-05-21 Grace W R Ab PROMOTER FOR PAPER SIZING, METHOD FOR THE PRODUCTION AND USE THEREOF
KR900701285A (en) 1988-08-26 1990-12-01 로버어트 에이 아미테이지 Micro-Beaded Cholestipol Hydrochloride
GB8829835D0 (en) 1988-12-21 1989-02-15 Smith Kline French Lab Compounds
DE3901527A1 (en) 1989-01-20 1990-07-26 Hoechst Ag ALKYLATED POLYETHYLENE IMIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS MEDICINAL PRODUCTS AND PHARMACEUTICAL PREPARATIONS
US6274713B1 (en) 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US5236701A (en) 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
US5136032A (en) 1989-12-07 1992-08-04 Daicel Chemical Industries, Ltd. Method for separating phosphopolyol compounds using a separating agent
US5053423A (en) 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
JPH0687974B2 (en) 1990-03-27 1994-11-09 忠一 平山 Adsorption material for heat generating substances
DE4010271A1 (en) 1990-03-30 1991-10-02 Basf Ag METHOD FOR PRODUCING ETHYLENE POLYMERISATS AT PRESSURES ABOVE 500 BAR IN A PIPE REACTOR WITH INJECTION FINGER
IE914179A1 (en) 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
RU1808015C (en) 1990-12-27 1993-04-07 Владимир Андреевич Шевченко Method of mammalian protection against gamma-irradiation
US5055197A (en) 1991-04-05 1991-10-08 Rohm And Haas Company Process for removing residual monomers and oligemers from amine-containing polymers
US5108767A (en) 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
WO1993000915A1 (en) 1991-07-03 1993-01-21 The Upjohn Company Colestipol hydrochloride high-content tablets
EP0534304A1 (en) 1991-09-21 1993-03-31 Hoechst Aktiengesellschaft Cycloalkylated polyethylenimines and their use as hypolipemic agents
SE470006B (en) 1991-09-26 1993-10-25 Corline Systems Ab New conjugate, its preparation and use, and substrates prepared with the conjugate
DK0580079T3 (en) 1992-07-22 1997-06-30 Hoechst Ag Cross-linked, nitrogen-containing vinyl copolymers, processes for their preparation and use of these compounds
EP0580078B1 (en) 1992-07-22 1997-10-15 Hoechst Aktiengesellschaft Hydrophilic groups containing poly(vinylamine) derivatives, process for their manufacture and use thereof as pharmaceutical compounds, substrates for active substances and foodstuff ingredients
PL307527A1 (en) 1992-08-20 1995-05-29 Du Pont Crosslinked polymeric ammonium salts
US5302531A (en) 1992-10-22 1994-04-12 Miles Inc. Composition for the semiquantitative determination of specific gravity of a test sample
EP0605757B1 (en) 1992-11-25 2001-08-16 Ajinomoto Co., Inc. Compositions and goods containing minerals and poly-gamma-glutamic acid
GB2276170B (en) 1993-02-17 1997-04-16 British Tech Group Polymers containing guanidine groups for use in therapy
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
EP0706399A4 (en) 1993-06-02 1998-08-12 Geltex Pharma Inc Compositions and process for removing bile salts
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
JPH0788181A (en) * 1993-09-21 1995-04-04 Mitsubishi Rayon Co Ltd Endotoxin adsorbent and manufacturing method
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
WO1996021454A1 (en) 1995-01-12 1996-07-18 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
GB9503061D0 (en) 1995-02-16 1995-04-05 British Tech Group Polymeric compounds
JP2936129B2 (en) 1995-04-12 1999-08-23 セイコー精機株式会社 Anti-corrosion structure
FI104823B (en) 1996-06-24 2000-04-14 Borealis Polymers Oy Anti-fouling coating
TW592727B (en) 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
JP3389493B2 (en) 1997-04-04 2003-03-24 中外製薬株式会社 Phosphate-binding polymer preparation
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
DE19835467A1 (en) 1998-08-06 2000-02-17 Elenac Gmbh Solid reactor with antistatic coating for carrying out reactions in the gas phase
TW568788B (en) 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
US6500527B2 (en) 2001-02-01 2002-12-31 3M Innovative Properties Company Image receptor sheet
EP1392331B1 (en) * 2001-04-18 2008-04-02 Genzyme Corporation Use of colesevelam or sevelamer hydrogen chloride for lowering serum glucose
ITMI20021718A1 (en) 2002-07-31 2004-02-01 Sematic Italia Spa SAFETY SWITCH WITH ELECTRONIC PROGRAMMABLE SYSTEM.
CA2551528A1 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
US20060024368A1 (en) 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
JPWO2006041150A1 (en) * 2004-10-15 2008-05-22 田辺三菱製薬株式会社 Diabetes prevention and / or treatment
US20060177415A1 (en) 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
EP2016947A1 (en) * 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Novel one step process for preparing cross-linked poly(allylamine) polymers
PA8807201A1 (en) * 2007-12-14 2009-07-23 Genzyme Corp PHARMACEUTICAL COMPOSITIONS
CN105017481B (en) 2010-02-24 2018-10-02 瑞立普萨公司 Cross-linked polyvinylamine, polyallylamine as bile acid sequestrant and aziridine
ES2661079T3 (en) * 2010-02-24 2018-03-27 Relypsa, Inc. Amine polymers for use as bile acid sequestrants
EP3130343B1 (en) 2010-02-24 2018-05-09 Relypsa, Inc. Polyimidazoles for use as bile acid sequestrants
US20130156720A1 (en) * 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
AU2014235500A1 (en) * 2013-03-15 2015-11-05 Genzyme Corporation Sequestrants of advanced glycation end product (AGE) precursors

Also Published As

Publication number Publication date
US11267924B2 (en) 2022-03-08
JP2018501358A (en) 2018-01-18
TW201636030A (en) 2016-10-16
MA41202A (en) 2017-10-24
CA2971204A1 (en) 2016-06-23
CO2017007119A2 (en) 2017-08-18
US20160177019A1 (en) 2016-06-23
JP2021063229A (en) 2021-04-22
PE20171510A1 (en) 2017-10-20
WO2016100456A2 (en) 2016-06-23
DOP2017000140A (en) 2017-07-31
UY36457A (en) 2016-07-29
CL2017001579A1 (en) 2018-03-23
JP6866293B2 (en) 2021-05-12
KR20170096008A (en) 2017-08-23
ECSP17045972A (en) 2017-11-30
EP3233090A2 (en) 2017-10-25
PH12017501120A1 (en) 2018-01-08
CN107250189A (en) 2017-10-13
AU2015362590A1 (en) 2017-08-03
HK1251449A1 (en) 2019-02-01
TN2017000253A1 (en) 2018-10-19
AR103175A1 (en) 2017-04-19
CR20170323A (en) 2017-08-22
BR112017012794A2 (en) 2018-01-02
MA40697A1 (en) 2018-01-31
MX2017007966A (en) 2018-03-15
EA201791380A1 (en) 2018-03-30
WO2016100456A3 (en) 2016-08-18
IL252899A0 (en) 2017-08-31
GT201700133A (en) 2019-09-17

Similar Documents

Publication Publication Date Title
IL275482A (en) Esketamine for the treatment of depression
EP3332717A4 (en) Treatment device
GB201608885D0 (en) Treatment
GB201502137D0 (en) Treatment
GB201522243D0 (en) Treatment
EP3056599A4 (en) Clothing treatment device
IL252899A0 (en) Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
PL3145511T3 (en) Composition for treating the eye
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
PL3484475T3 (en) 1-methylnicotinamide for the treatment of cardiovascular disease
GB201519450D0 (en) Novel treatment
EP3305975A4 (en) Clothing treatment device
GB201508841D0 (en) Treatment
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
GB201620323D0 (en) Treatment Device
GB201411027D0 (en) Treatment
EP3323368A4 (en) Treatment too
GB201503008D0 (en) Treatment
GB201418541D0 (en) Materials for use with general hyperthermia treatment
GB201412411D0 (en) Treatment
GB201718985D0 (en) Treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201617107D0 (en) Treatment